* Pacira Biosciences Inc is expected to show a rise in quarterly revenue when it reports results on November 1 (estimated) for the period ending September 30 2024
* The Tampa Florida-based company is expected to report a 3.5% increase in revenue to $169.672 million from $163.93 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Pacira Biosciences Inc is for earnings of 70 cents per share.
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 4 "hold" and 2 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Pacira Biosciences Inc is 18.00, above its last closing price of $17.18.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 0.71 0.70 0.89 Beat 27.3
Mar. 31 2024 0.61 0.62 0.62 Met -0.6
Jan. 1 0001 0.88 0.88 0.89 Beat 0.7
Sep. 30 2023 0.77 0.78 0.72 Missed -8.2
Jun. 0.77 0.76 0.78 Beat 2.9
30 2023
Mar. 31 2023 0.62 0.62 0.53 Missed -14.1
Dec. 31 2022 0.82 0.83 0.80 Missed -3.6
Jan. 1 0001 0.71 0.76 0.64 Missed -16.2
This summary was machine generated October 30 at 13:29 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments